コーパス検索結果 ( right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 ortical gray-matter thickness in the methamphetamine group, but no association was found between gray-matter thickness an
2 sociation between plasma organophosphate residues and HbA1c but no association with acetylcholine esterase was noticed.
4 r the past two decades have yielded some important insights but no blockbuster drugs to alter the course of disease.
5 s liked the tastes of carrot, beet, and celery juices more, but no changes in dietary intake of vegetables were observed.
6 deposition of RNAPII-Ser5P, the initiating form of RNAPII, but no changes in H3K27me3, at the promoters of affected endo
7 to detect Chlamydia trachomatis and Neisseria gonorrhoeae, but no commercial tests are cleared by the U.S. Food and Drug
8 ment length is controlled involves the giant protein titin, but no conclusive support for this hypothesis exists.
9 13 (65%) of 20 intervention participants, but no control participants, passed MLMT at the lowest lumina
10 tive correlation with the anti-cod PAV polyclonal antibody, but no correlation with the anti-carp PAV monoclonal antibody
12 ed ePPIX levels and symptoms consistent with protoporphyria but no detectable mutation in the FECH or ALAS2 (OMIM 301300)
13 e, 67.9 years; 35.3% women; 31.2% blacks) with hypertension but no diabetes mellitus from the SPRINT trial (Systolic Bloo
15 children with ASD and OCD compared with controls (p=0.007), but no differences between the two disorders (p=0.770).
16 tes are distributed into circulating and marginating pools, but no direct evidence of the latter has been obtained so far
17 a robust induction of depressed mood in the control group, but no effect in the supplement group [43.85 +/- 18.98 mm vs.
18 aratory motor activity following PA in healthy participants but no effect on attention-related activity.
20 suppression when transplanting an old kidney may be useful, but no formal trials are available.Old donors constitute an e
22 l fragments (APP-CTFs) and oligomeric amyloid beta (oAbeta) but no histological evidence of amyloid deposition.
23 hazard of infection (hazard ratio, 2.18; 95% CI, 1.90-2.51) but no increased odds of mortality (odd ratio, 1.07; 95% CI,
25 rystalline materials, where tiling units arrange with local but no long-range order, remains challenging.
26 quirements will include added sugars starting in July 2018, but no measure currently exists to identify the added sugar c
27 ts (29 with IBS and 17 healthy subjects); 46 fecal samples, but no mucosal samples, were collected and analyzed.
28 h RAI had an increased early risk of developing AML and CML but no other hematologic malignancies.
29 Two-hybrid and pulldown assays demonstrated that UL20, but no other HSV-1 gene-encoded proteins, binds specifically
31 Synergy between these factors has been suggested, but no physiological mechanism has been identified.
32 an and macaque infants are sensitive to absolute disparity, but no previous study has specifically studied the developmen
34 auma at either blood draw (n = 175), trauma at blood draw 1 but no PTSD at either draw (n = 175), and PTSD that persisted
35 type 3, Y93H was associated with resistance to daclatasvir, but no RASs were associated with ledipasvir failure, pointing
36 rbal brain tonic for mental disorders and enhancing memory, but no review of the overall evidence of C. asiatica and cogn
38 an increase in RRPtrain during PTP in both control and cKO, but no significant changes in the PPR.
39 03 versus 320 pg/mL; all P<0.01), more signs of congestion, but no significant difference in left ventricular ejection fr
40 t patients (from -2.26 g/L per year to -1.26 g/L per year), but no significant difference was seen in the rate in early-s
41 replication and production of viral progeny in SCG neurons, but no significant differences were found in TG neurons.
42 d MMP-9 and an accumulation of cytoplasmic MMP-2 over time, but no significant MMP-3 or MMP-8 production was observed.
43 Mutations explaining GSD Ia and DGS were found but no specific causative mutation for cataract and ONHD.
44 Statin treatment starts at diagnosis, but no statin has been formally evaluated in, or approved for
45 (hazard ratio: 2.19; 95% confidence interval: 1.07 to 4.46) but no statistically significant difference in stroke (3 NOAC
46 ne seems to be associated with a low rate of serious harms, but no study evaluated risks of transport versus nontransport
47 suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its us
48 ases that involve increased alternative pathway activation, but no therapeutic factor H is commercially available.
49 cause of hand, foot and mouth disease in children worldwide but no vaccine is available against CVA6 infections.
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。